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Background: Tumor necrosis factor-α (TNF) is strongly implicated in the development 
of acute respiratory distress syndrome (ARDS), but its potential as a therapeutic target 
has been hampered by its complex biology. TNF signals through two receptors, p55 and 
p75, which play differential roles in pulmonary edema formation during ARDS. We have 
recently shown that inhibition of p55 by a novel domain antibody (dAb™) attenuated ven-
tilator-induced lung injury. In the current study, we explored the efficacy of this antibody 
in mouse models of acid-induced lung injury to investigate the longer consequences of 
treatment.
Methods: We employed two acid-induced injury models, an acute ventilated model 
and a resolving spontaneously breathing model. C57BL/6 mice were pretreated intratra-
cheally or intranasally with p55-targeting dAb or non-targeting “dummy” dAb, 1 or 4 h 
before acid instillation.
results: Acid instillation in the dummy dAb group caused hypoxemia, increased respi-
ratory system elastance, pulmonary inflammation, and edema in both the ventilated and 
resolving models. Pretreatment with p55-targeting dAb significantly attenuated physio-
logical markers of ARDS in both models. p55-targeting dAb also attenuated pulmonary 
inflammation in the ventilated model, with signs that altered cytokine production and 
leukocyte recruitment persisted beyond the very acute phase.
conclusion: These results demonstrate that the p55-targeting dAb attenuates lung injury 
and edema formation in models of ARDS induced by acid aspiration, with protection 
from a single dose lasting up to 24 h. Together with our previous data, the current study 
lends support toward the clinical targeting of p55 for patients with, or at risk of ARDS.
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inTrODUcTiOn
Acute respiratory distress syndrome (ARDS) is a major cause of patient morbidity and mortality 
within the ICU, constituting ~10% of ICU admissions worldwide with an associated mortality of 
30–50% (1). ARDS can result from various insults, of which aspiration of acidic gastric contents 
is a major contributor both within the community and in the operating theater during anesthesia 
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(2). Inflammation has been considered to be key in developing 
ARDS, but attempts to minimize “global” inflammation, e.g., by 
use of corticosteroids have delivered limited mortality benefits 
(3–7), suggesting the need for a more targeted approach. Among 
all potential targets, tumor necrosis factor-α (TNF) is one of the 
strongest candidates for such interventions—it is one of the 
earliest expressed “gate-keeper” cytokines in response to almost 
any potentially damaging situation, modulating subsequent 
inflammatory responses, and has been repeatedly implicated in 
the development and progression of ARDS (8), including direct 
effects on pulmonary edema formation and clearance. Despite 
this, previous clinical trials of anti-TNF therapy have shown 
little beneficial impact within the ICU setting (9). This may be 
partly attributed to the biophysical properties of the inhibitors 
used (e.g., affinity and tissue penetration), and also likely related 
to the complex nature of TNF signaling.
Tumor necrosis factor signals through two cell surface 
receptors, TNF receptor (TNFR) type I (p55) and TNFR type II 
(p75). Historically, p75 signaling was considered to be adjunct 
to the p55 pathway (10, 11), but it is now becoming clear that 
each TNFR subtype has signaling capabilities of its own, which 
in particular circumstances may lead to directly opposing 
consequences (12–16). In line with this, we have previously 
shown using genetically modified mice that specific absence 
of p55 is protective in the very acute phase of ARDS induced 
by mechanical ventilation (17), while absence of p75 seems to 
be detrimental. We have also found that p55 signaling triggers 
alveolar epithelial cell dysfunction in the early phase of ARDS, 
promoting lung permeability as well as impairing alveolar fluid 
reabsorption (18). These findings suggest that while total TNF 
signaling blockade would likely be counterproductive, specific 
therapeutic strategies targeting the individual TNFRs could be 
effective in ARDS.
We have recently demonstrated efficacy of selective pharma-
cological blockade of p55 signaling in an acute model of mouse 
ventilator-induced lung injury (VILI), using a novel IgG frag-
ment known as a domain antibody (Biopharmaceuticals R&D, 
GlaxoSmithKline, Stevenage, UK) (19). Domain antibodies 
(dAb™) offer multiple advantages over conventional antibody 
technology (20)—for example, they have fewer off-target 
effects and can be delivered at much higher concentrations 
per unit mass compared to conventional antibodies due to the 
lack of an Fc region and can be manufactured to be suitable 
for local delivery such as inhalation. In the current study, we 
tested the efficacy of a dAb antagonist of murine p55, in mouse 
models of acute and resolving acid aspiration-induced lung 
injury (21). This enabled us to both evaluate the acute benefits 
of pharmacological p55 blockade in a highly clinically relevant 
model and explore whether any beneficial effects persisted 
beyond the acute stage. A  similar dAb antagonist of human 
p55 has recently entered early clinical development for lung 
injury (22).
MaTerials anD MeThODs
All protocols were approved by the Ethical Review Board of 
Imperial College London and carried out under the authority of 
the UK Home Office in accordance with the Animals (Scientific 
Procedures) Act 1986, UK. Male C57BL/6 mice (Charles River, 
Margate, UK) aged 9–12 weeks old, weighing 25–30 g were used 
throughout.
The p55-targeting dAb sequence was identified from a phage 
display library. To determine binding kinetics, murine p55 or 
p75 was immobilized on an IgG surface, varying concentrations 
of dAb (from 0.25 to 16 nM) were passed over the surface, and 
interactions were evaluated via surface plasmon resonance using 
a Biacore T200 system. Association constant (ka) of the dAb 
for p55 was determined as 3.455 × 107 (1/Ms) and dissociation 
constant (kd) was 0.0014 (1/s), indicating high affinity of binding 
(KD) of 4.05 × 10−11M, assuming a 1:1 binding stoichiometry. In 
contrast, no specific binding was observed to p75.
Ventilated acid aspiration Model
We have previously shown that genetic absence of TNFR p55 
signaling attenuates pulmonary edema formation during the 
first 2–3 h after acid instillation in mice (18). Therefore, initial 
experiments were carried out to determine whether p55 dAb 
administration would have a similar influence during the acute 
phase of acid aspiration-induced lung injury.
Mice were anesthetized (intraperitoneal ketamine 80  mg/kg 
and xylazine 8  mg/kg), tracheostomized, and connected to a 
custom-made ventilator/pulmonary function testing system as 
described previously (23). Animals had a cannula placed in the 
carotid artery for monitoring of blood pressure, blood gas analy-
sis, and fluid replacement. All animals were ventilated using 7 ml/
kg tidal volume, 2.5  cmH2O positive end-expiratory pressure 
(PEEP), and respiratory rate of 120/min, with 100% O2. Following 
instrumentation, either specific murine TNFR p55 blocking dAb 
(Dom-1m-15-12, GSK) or non-targeting control dAb (“dummy”) 
was intratracheally delivered in bolus form (25 µg of antibody in 
a volume of 50 µl) via a fine cannula passed through the endotra-
cheal tube. The lungs were then immediately recruited with four 
sustained inflation maneuvers (35  cmH2O, 5  s) to maximize 
distribution of the antibody into the lungs. Mice were ventilated 
for 1 h to allow respiratory mechanics to return toward normal, 
and then 65 µl of 0.075M hydrochloric acid (HCl) was instilled 
into the trachea through the endotracheal tube. Lungs were again 
recruited by sustained inflations, and mice were ventilated for a 
further 3 h. Anesthesia was maintained by bolus administrations 
of intraperitoneal ketamine (40 mg/kg) and xylazine (4 mg/kg) 
every 20–25 min.
Airway pressure and arterial blood pressure were monitored 
continuously. Plateau pressure, and respiratory system elastance 
and resistance were determined every 20 min by the end-inflation 
occlusion technique, followed each time by sustained inflation 
(35 cmH2O for 5 s) to avoid the development of atelectasis (23). 
Arterial blood gases were assessed at predetermined points 
throughout the protocol (immediately before, 60, 120, and 
180 min after acid instillation). At the end of the experiments, 
animals were exsanguinated, lung lavage was performed using 
750 µl of saline, and lung tissue samples were taken for further 
analysis. Each animal was experimented on a separate day, so 
each observation reflects an independent experiment.
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spontaneously Breathing Model  
of acid aspiration
While the use of mechanical ventilation provides many advan-
tages, including real-time cardiorespiratory monitoring and an 
ability to directly compare findings with those of our previous 
studies in genetically modified animals (18), by definition the 
model is limited to investigation within the acute phase. We have 
recently developed a spontaneously resolving model of acid aspi-
ration-induced lung injury (21), which, unlike a number of other 
models, mimics most of the features of clinical ARDS over up to 
5–10 days (24–26). We therefore employed this resolving model 
to investigate the impact of intranasally delivered p55-targeting 
dAb on the later phases of injury/start of the repair process.
All animals were anesthetized briefly with inhalational 
isoflurane (2%) and intranasally dosed with 100 µg (50 µl total 
volume, divided into two nostrils) of either p55-targeting dAb 
or dummy dAb. Four hours after dosing (a period designed to 
allow distribution of the antibody and full recovery of respiratory 
mechanics from the nasal dosing procedure under non-ventilated 
conditions), animals were reanesthetized either for physiological 
analysis (see below—0 h mice) or for acid instillation according to 
our previously published protocols (21). In brief, mice were sus-
pended vertically for orotracheal instillation, and a fine catheter 
passed through the vocal cords. A total of 75 µl of an isoosmolar 
solution of 0.1M hydrochloric acid (pH 1.0) was instilled, and 
mice received an intraperitoneal bolus of 0.9% saline for fluid 
resuscitation. Mice were maintained in a humidified chamber 
containing supplemental oxygen (decreasing from FiO2 1.0–0.4) 
over the next 4 h and were then returned to individually ventilated 
cages. Due to the nature of the dosing technique and postdosing 
care requirements, a maximum of three animals were dosed 
with acid/antibody on a single day. Each set of data shown in the 
Section “Results,” of any given combination of treatment (dummy 
versus p55-targeting dAb) and time point (0, 24, 48, and 72 h), 
therefore represents observations from 5 to 8 mice, obtained from 
3 to 4 independent experiments.
Physiological analysis was carried out at predetermined end 
points, i.e., 0, 24, 48, or 72 h post acid. Mice were anesthetized 
(ketamine 80  mg/kg, xylazine 8  mg/kg) and instrumented as 
described for the acute ventilated model. Immediately after com-
pleting surgical preparation, lungs were recruited by sustained 
inflation (35  cmH2O for 5  s). Mice were then ventilated with 
7 ml/kg tidal volume, 2.5 cmH2O PEEP, and respiratory rate of 
120/min using 100% O2 for 30 min, in order to standardize the 
volume history of the lung and determine the PaO2/FiO2 ratio 
from carotid blood samples (21). At the end of 30 min ventila-
tion, respiratory mechanics and blood gases were evaluated, and 
animals were terminated by exsanguination. The right lung was 
tied off at the hilum, weighed, and placed in an oven at 60°C for 
determination of wet:dry weight ratio. The left lung was lavaged 
using 400 µl saline and dissected out for further analysis.
evaluation of injury and inflammation  
in lavage samples
Total protein concentration in lung lavage fluid was measured 
as an indicator of alveolar-capillary permeability (Bio-Rad, 
Hertfordshire, UK). Concentrations of interleukin 6 (IL-6), the 
neutrophil chemoattractants CXCL1 and CXCL2, and the mono-
cyte chemoattractant CCL2 were measured by ELISA (R&D 
Systems, Abingdon, UK). The number of neutrophils in lavage 
fluid was determined by microscopic cytology using hemocytom-
eter and Cytospin-prepared slides.
lung Tissue Flow cytometry
The identification and quantification of leukocytes within 
lung tissue was performed by flow cytometry using methods 
described and validated previously. For the acute ventilated 
model, lung samples were removed, minced, and passed through 
a 40 µm filter (19, 27). Samples were resuspended in a washing 
buffer (PBS with 2% FCS, 0.1% sodium azide, and 5 mM EDTA) 
and stained for 30  min in the dark at 4°C with fluorophore-
conjugated anti-mouse antibodies for CD11b (clone M1/70), 
Gr-1 (RB6-8C5) (both BD BioSciences), and F4/80 (CI:A3-1) 
(Biolegend). For the spontaneously breathing resolution model, 
the potential for influx of other cell types over time led us to 
modify this approach for further identification of leukocyte 
subpopulations (18). Lung tissues were excised and fixed with 
Cytofix/Cytoperm (BD Biosciences, Oxford, UK), mechanically 
disrupted by gentleMACS Dissociator (Miltenyi Biotech, Surrey, 
UK) and passed through a 40  µm filter to prepare single-cell 
suspensions. Samples were then stained for 30  min in the 
dark at 4°C with fluorophore-conjugated anti-mouse antibod-
ies for CD11b, Gr-1, Ly6C (AL-21), and NK1.1 (PK136) (BD 
BioSciences). Importantly, we showed previously (28) that 
although the Gr-1 antibody used (clone RB6-8C5) binds both 
Ly6G and Ly6C epitopes under non-fixed conditions (i.e., for 
the acute ventilated model), the use of Cytofix/Cytoperm results 
in loss of Ly6C recognition by the antibody. Therefore, in the 
context of the resolution model, Gr-1 staining is representative 
solely of cell Ly6G expression. Cell samples were analyzed by a 
CyAn flow cytometer with Summit software (Beckman Coulter, 
High Wycombe, UK), and further data analysis was performed 
by FlowJo software (Tree Star, Ashland, OR). Absolute leukocyte 
counts were determined using microsphere beads (Invitrogen, 
Paisley, UK).
statistical analysis
Statistical analyses were performed using SPSS version 22 (IBM, 
Portsmouth, UK). The normality of model residuals was assessed 
by QQ plot and Shapiro–Wilk test. Data that were not normally 
distributed were transformed (see legends for details), and sub-
sequent parametric distribution confirmed before analyses were 
carried out. Data that could not be normalized by transformation 
were analyzed using non-parametric tests. Time-course data in 
the acute ventilated model were analyzed by repeated measures 
analysis of variance (ANOVA) followed by pairwise analysis of 
individual time points, while end-point analyses were carried 
out by Student’s t-test. In the resolving injury model, differences 
between treatment groups were evaluated on each day, using 
either Student’s t-test or Mann–Whitney U-test. A value of 
p < 0.05 was considered significant.
FigUre 1 | Peak inspiratory pressure (a) and arterial blood pressure (B) in ventilated animals following intratracheal treatment with dummy dab, 
followed by challenge with either intratracheal saline or hydrochloric acid. N = 4 (dummy + saline), or 6 (dummy + acid) at each time point. Data are 
expressed as mean ± SD.
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resUlTs
acute Model
We first carried out experiments to determine the influence of 
p55-targeting dAb administration on the acute phase of acid 
aspiration-induced lung injury. As part of the model develop-
ment, experiments were performed comparing the physiological 
consequences of acid instillation versus those of saline instillation. 
Initial administration of dummy dAb led to a transient increase 
in peak inspiratory pressure (Figure 1A), which returned toward 
normal as fluid was distributed and absorbed within the lungs 
(the same pattern was apparent following administration of 
p55-targeting dAb; data not shown). Instillation of either saline 
or acid 60 min later caused similar increases in airway pressure. 
In animals receiving saline, peak inspiratory pressure decreased 
and plateaued. In contrast, animals that received acid instillation 
showed an initial improvement in airway pressure, which then 
deteriorated over the final 60 min. Intratracheal administrations 
also caused small, transient decreases in blood pressure, most 
likely secondary to the sustained inflation maneuvers carried 
out to distribute instilled fluids (Figure 1B). Blood pressure was 
otherwise well maintained throughout the experiments until the 
final 60 min during which it deteriorated somewhat, particularly 
in acid-treated animals.
The physiological consequences of acid instillation were then 
compared between animals pretreated with either the dummy 
non-targeting dAb or the p55-targeting dAb (N = 6 independ-
ent experiments/group). The initial mechanics response to acid 
was similar between the two groups (Figure  2A), consisting 
of a transient spike in elastance followed by a return toward 
pre-instillation levels. In the dummy dAb group, elastance then 
increased from ~100 min until the end, whereas in contrast, the 
p55-targeting dAb-treated mice showed little increase, resulting 
in a significantly attenuated elastance change (p value for interac-
tion <0.01, although pairwise analysis did not detect significant 
differences at individual time points). Respiratory system resist-
ance showed similar patterns in both groups, consisting of a 
decrease following acid instillation that remained relatively stable 
thereafter (Figure 2B). There was also a decrease in arterial pO2 
and an increase in pCO2 during the final hour of ventilation in 
dummy-treated animals (Figures 2C,D). These impairments in 
gas exchange were significantly attenuated by treatment with the 
p55-targeting dAb (p-value for interaction <0.05, with pairwise 
analysis showing significant difference at the 180 min time point).
Lung lavage fluid in the dummy-treated group contained 
a substantial amount of protein, indicating an increase in epi-
thelial/endothelial barrier permeability (Figure 3A, dotted line 
represents data from saline-treated animals for visual compari-
son). This was somewhat, though not significantly, reduced by 
p55-targeting dAb. Evaluation of pro-inflammatory cytokines in 
lung lavage fluid showed that IL-6 and CXCL1 showed a tendency 
to be reduced, while CXCL2 and CCL2 were significantly attenu-
ated in p55-targeting dAb-treated mice (Figures 3B–E).
Finally, lung leukocyte recruitment was determined in each 
group of mice. Neutrophil infiltration into the alveolar space 
(evaluated by microscopic cytology of lung lavage fluid) was 
significantly attenuated by p55-targeting dAb (Figures  4A,B). 
Total lung tissue neutrophil and monocyte recruitment were 
evaluated by flow cytometry (Figure  4C). Neutrophil recruit-
ment was somewhat (though not significantly) reduced follow-
ing p55-targeting dAb, while inflammatory Ly6Chi monocyte 
numbers were significantly attenuated (Figures 4D,E).
resolving Model
While the data from the acute model indicate that intratracheal 
inhibition of p55 using the dAb attenuates both pulmonary edema 
and inflammation during the early phase of ALI/VILI, it does 
not necessarily follow that this would translate to a prolonged 
benefit. We therefore carried out experiments to investigate the 
consequences of p55-targeting dAb on the later phase of ALI 
using the resolving model.
Acid instillation caused a clear physiological lung injury in 
dummy dAb-treated animals, consistent with previous reports 
using this model (21, 29). Respiratory system elastance (deter-
mined after 30  min of ventilation) was increased at 24  h after 
acid, and subsequently returned toward baseline although did 
not reach normal values by day 3 (Figure 5A). Similarly, arterial 
pO2 was substantially decreased (Figure 5B) and pCO2 increased 
FigUre 2 | respiratory system elastance (a) and resistance (B), and arterial pO2 (c) and pcO2 (D) following acid instillation in animals treated with 
dummy or p55-targeting dab. Mechanics data are expressed as % increase following acid. Elastance data (a) were log-transformed to achieve normal 
distribution, while pO2 (c) was normalized by raising to the power of 2. These data are displayed as back-transformed mean with error bars representing 90% 
confidence intervals. Resistance data and pCO2 were normally distributed and thus displayed as mean ± SD. Repeated measures analysis of variance revealed 
significant interactions between treatment and time for elastance change (p < 0.01), pO2 (p < 0.05), and pCO2 (p < 0.01). *p < 0.05 between dummy and 
dAb-treated animals at 180 min after acid. N = 5–6 observations from independent experiments at each time point.
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(Figure 5C) 1 day after acid. pO2 remained low at day 2 and then 
started to recover at day 3, while pCO2 showed some signs of 
return toward normal at day 2. The single pretreatment with 
p55-targeting dAb led to a significant attenuation in each of these 
parameters at 24 h. It was clear however that by 48 h most of the 
protection afforded by the dAb was lost, with animals appearing 
as injured as dummy dAb-treated mice. Acid instillation also 
caused increases in pulmonary edema/permeability, assessed by 
lavage fluid protein (Figure 5D) and lung wet:dry weight ratio 
(Figure  5E). Both of these markers peaked around days 1–2 
before returning toward (but not achieving) baseline levels by 
day 3. Pretreatment with the p55-targeting dAb reduced lavage 
fluid protein levels (again, only at day 1) and lung wet:dry ratio 
(at days 1 and 2).
Finally, the effect of p55-targeting dAb on inflammation 
within the lungs was evaluated after acid instillation. Lavage 
fluid CXCL1 (Figure 6A) was increased to a variable degree in 
dummy dAb-treated animals, but still significantly attenuated at 
days 1 and 2 following p55-targeting dAb. In contrast, levels of 
CCL2 (Figure  6B) were similar between the treatment groups 
on all days, and unlike CXCL1, did not return to baseline by day 
3. Neutrophil infiltration into the alveolar space (by differential 
cytology) was highly variable and showed little difference between 
treatment groups (Figures 6C,D), apart from a small reduction 
in neutrophil percentage at day 2 following p55-targeting dAb. 
Lung tissue recruitment of neutrophils and Ly6Chi monocytes, 
evaluated by flow cytometry (Figure 6E), showed large increases 
between 24 and 48 h after acid in dummy dAb-treated animals 
(Figures  6F,G), consistent with previously published kinetics 
in this model of injury (30). However, there was no significant 
difference in cell recruitment with p55-targeting dAb, apart from 
a reduction in Ly6Chi monocytes at day 3.
DiscUssiOn
Despite much research, and major advances in our understand-
ing of the pathophysiology, effective pharmacological therapies 
for ARDS patients remain elusive. It is generally accepted that 
inflammation plays an important role in ARDS, and numerous 
drug targets have been identified within preclinical settings, but 
none of these have translated into clinical treatment. The reasons 
for this have been widely discussed, including the recent debate 
regarding the similarity of inflammatory responses between 
rodents and humans (31, 32), and the possible different responses 
of ARDS subphenotypes (33). Perhaps more to the point is that 
animal models of ARDS generally replicate a limited number 
of the features seen in patients (24, 25). Many models are either 
too severe/invasive to explore longer consequences (i.e., animals 
cannot be studied beyond the acute phase) or too mild to repli-
cate the complex pathology. Thus, these models often have very 
limited predictive power, particularly when they are considered 
in isolation, in terms of the consequences of inhibiting pathways. 
FigUre 3 | lavage fluid levels of total protein (a), interleukin 6 (B), cXcl1 (c), cXcl2 (D), and ccl2 (e) 180 min after acid instillation in animals 
treated with dummy or p55-targeting domain antibody. Dotted lines represent data from saline-treated animals for visual comparison. Lavage fluid CXCL2 (D) 
required log-transformation to normal distribution and is therefore displayed as geometric mean with error bars representing 90% confidence intervals. All other data 
were normally distributed and thus are displayed as arithmetic mean ± SD. T-tests were used to evaluate differences between treatments. N = 5 observations from 
independent experiments for each group (corresponding to the total number of mice assessed for these parameters).
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For this reason, in the current study, we explored the impact of 
a domain antibody (dAb™) targeting the p55 TNFR, which we 
previously showed to be efficacious in attenuating VILI in mice 
(19), in more clinically relevant acute and resolving models of 
acid aspiration-induced lung injury.
In the acute ventilated model, the data demonstrate a very 
clear attenuation of injury in the animals receiving p55-targeting 
dAb. Specifically, respiratory mechanics and blood gases were 
significantly preserved. While pairwise analysis of individual 
time points indicated that only pO2 and pCO2 showed signifi-
cant differences, and then only at the final time point, repeated 
measures ANOVA demonstrated clear interaction effects for 
elastance, pO2 and pCO2. Given that the repeated measures 
ANOVA both maximizes the data being utilized within any given 
analysis and decreases the chance of type II error by reducing 
within group variability, these data show that the development of 
“physiological injury” over time was attenuated by the adminis-
tration of p55-targeting dAb. We did not evaluate lung histology 
in these animals, although respiratory system mechanics and 
blood gasses are clinically important parameters crucial for the 
diagnosis of ARDS, which are not always evaluated within ani-
mal models. We have previously evaluated histological changes 
FigUre 4 | recruitment of leukocytes into the alveolar space (a,B), and lung tissue (c–e), 180 min after acid instillation in animals treated with 
dummy or p55-targeting domain antibody. For the acute ventilated model, tissue neutrophils were identified as CD11bhigh, Gr-1high, F4/80 negative events, while 
monocytes were identified as CD11bhigh, F4/80 positive events, and differentiated by their expression of Gr-1. Under the non-fixed conditions used for these 
experiments, the Gr-1 antibody used (clone RB6-8C5) binds both Ly6G and Ly6C epitopes. Panel (c) shows side-by-side representative flow cytometric plots for 
lungs from dummy dAb and p55-targeting dAb-treated animals. Cell numbers were determined by use of fluorescent counting beads and expressed as total cell 
counts in both lungs (D,e). Data are displayed as mean ± SD, with t-tests used to evaluate differences. N = 4–5 observations from independent experiments for 
each group (corresponding to the total number of mice assessed for these parameters).
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within the acute and resolving acid-induced injury models (18, 
21) and showed that it correlates well with these other markers. 
In addition to the changes observed, lung permeability showed 
a tendency toward protection. Overall, these data are consistent 
with our previous investigations into acid-induced lung injury in 
genetically modified animals (18), confirming the importance of 
the p55 TNFR pathway in this model of pulmonary injury and 
edema formation. Interestingly, in that previous study, we found 
that “classic” inflammatory mediators (IL-6, CXCL1, CCL2) 
and leukocyte recruitment were unaffected by the absence of 
p55 signaling (18), while here we found quite clearly that the 
acute intratracheal inhibition of p55 using the dAb led to sig-
nificant attenuation of alveolar cytokine/chemokine levels, and 
reduced recruitment of neutrophils and inflammatory Ly6Chi 
monocytes. The reasons for this apparent difference may relate 
to consequences of compartmentalized inhibition of p55 signal-
ing versus whole body absence of p55, or the effects of chronic 
compensation of signaling pathways in genetically modified 
animals. A similar phenomenon is apparent when comparing 
genetic modification versus acute inhibition of p55 in models of 
VILI (17, 19) so although the underlying reasons are unclear, they 
are not model specific. An alternative explanation could be that 
the dAb has some additional “off-target” effects. We believe this is 
unlikely, as binding data demonstrated that dAb has high affinity 
binding to the p55 TNFR and no specific binding to the closely 
related p75 receptor. This could be clarified in future experiments 
by exploring the consequences of p55 dAb administration into 
p55 knockout mice.
A major aspect of the current study was to explore the influ-
ence of p55 inhibition beyond the very acute (3–4  h) phase; 
it may be dangerous to assume that any early consequences of 
p55 inhibition will continue to be beneficial into the later stages 
of disease progression, without understanding the knock-on 
effects of interfering with this pathway. For this reason, we 
FigUre 5 | Physiological indications of injury in the resolution model were determined in terms of elastance (a), arterial pO2 (B), and pcO2 (c) 
measured after 30 min ventilation with 100% O2. Data were evaluated for differences due to treatment on each day. Data did not achieve normal distribution 
even with transformation, and thus are displayed as box-whisker plots and analyzed using Mann–Whitney U-test. Error bars extend to maximum and minimum 
values, while markers within boxes show the median. Physiological parameters of injury were significantly attenuated by p55-targeting dAb treatment at day 1, but 
this was mostly lost by day 2. N = 5–8 for elastance and 5–7 for blood gases at each time point. Permeability/edema was evaluated by lavage fluid protein (D) and 
wet:dry weight ratio (e). Lavage fluid protein is displayed as box-whisker plots and was analyzed using Mann–Whitney U-test, while wet:dry weight is displayed as 
mean ± SD and was analyzed using Student’s t-test. N = 5–7 for lavage protein and 5–8 for wet:dry ratio at each time point.
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utilized a more chronic model of acid aspiration-induced injury 
developed within our research group (21). For the purposes of 
this study, we investigated the first 72 h after injury, a time frame 
that from our previous work encompasses the peak of injury and 
beginnings of a return toward homeostasis. In order to avoid 
frequent airway manipulation, we chose to use the intranasal 
route for delivery of domain antibody, followed by intratracheal 
acid instillation. Studies have estimated that the intranasal 
administration technique achieves approximately 50% delivery 
into the airspaces (34). This, combined with the fact that we 
were looking for consequences of domain antibody adminis-
tration over a much longer time period, led us to increase the 
antibody dose from 25 µg in the acute model to 100 µg. Within 
these experiments, we found that markers of respiratory system 
mechanics, blood gases, and edema/permeability were signifi-
cantly improved by the single pretreatment with p55-targeting 
dAb. However, for a number of these markers, most notably 
arterial pO2 and lavage fluid protein, the injury induced by acid 
FigUre 6 | inflammation within the resolution model was evaluated in terms of lavage fluid cytokines and leukocyte recruitment. Data were evaluated 
for differences due to treatment on each day. Lavage fluid CXCL1 (a) and CCL2 (B) could not be normalized and are displayed as box-whisker plots with analysis 
by Mann–Whitney U-test (N = 4–7 at each time point). CXCL1 levels were significantly attenuated following pretreatment with p55-targeting dAb, while CCL2 was 
unaffected. Neutrophil infiltration into the alveolar space (c,D) was highly variable. Neutrophil percentage was reduced at day 2 by dAb treatment, although numbers 
recruited were not significantly attenuated. For the resolution model neutrophils, monocytes, and NK cells within lung tissue were identified as CD45 positive, 
CD11bhigh events using flow cytometry, and differentiated by their expression of Gr-1 and NK1.1 [representative plots from dummy-treated mouse at 24 h after acid 
shown in panel (e)]. NK cells were identified as NK1.1 positive events. We showed previously (28) that although the Gr-1 antibody used (clone RB6-8C5) binds both 
Ly6G and Ly6C epitopes under non-fixed conditions, the use of Cytofix/Cytoperm results in loss of Ly6C recognition by the antibody. Therefore, in the current 
context, Gr-1 staining is representative of cell Ly6G expression. Within the NK1.1 negative events, neutrophils were thus identified as Gr-1 (Ly6G) high events, while 
Gr-1 (Ly6G) low events were designated as monocytes. These were further subcategorized based on expression of Ly6C. Total lung tissue recruitment of neutrophils 
(F) and Ly6Chi monocytes (g) were not different following dummy or p55-targeting dAb treatment, apart from a reduction in Ly6Chi monocytes at day 3. Neutrophil 
numbers in lung tissue (F) are displayed as mean ± SD, while Ly6Chi monocyte numbers (g) and neutrophils in lavage fluid (c,D) could not be normalized and are 
displayed as box-whisker plots (evaluated using Mann–Whitney U-test). N = 5–7 for each time point.
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was delayed rather than prevented. Thus, in general, most of the 
protective effects of a single dose of p55-targeting dAb treat-
ment in terms of physiology were lost after 24 h.
p55-targeting dAb treatment also influenced inflammatory 
markers within the chronic model, although these were less 
pronounced than the physiological findings. Levels of CXCL1 
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and lavage fluid neutrophils (percentage of alveolar cells) were 
attenuated at days 1–2, but CCL2 levels were not. Interestingly, 
there was no clear difference in numbers of lung tissue leukocytes 
on day 1 (or 2) after acid, at which point physiological injury 
was clearly attenuated following p55-targeting dAb. Ly6Chi 
monocyte recruitment was attenuated at day 3, and while these 
cells have been reported as being injurious in the acute phase 
of injury (27, 35, 36), the physiological relevance of the current 
finding is unclear. It is possible that this later phase of monocyte 
recruitment represents transmigration of a reparative subset (37), 
although this remains speculation.
Tumor necrosis factor-α, as a highly pleiotropic cytokine, 
plays a multitude of roles during the pathogenesis of ARDS, and 
these roles may themselves change during the progression of the 
syndrome from acute exudative to chronic resolution phases. 
The data from this study and our previous investigations (17–19) 
indicate that while TNF p55 signaling is involved in both physi-
ological injury/pulmonary edema formation and lung leukocyte 
recruitment, there is a clear lack of correlation between these two 
processes. Other pathophysiological mechanisms mediated by 
TNF may be more important in determining alveolar epithelial 
barrier function and fluid balance during ARDS than its role in 
recruiting leukocytes, which may involve more redundant path-
ways. Specifically, TNF has a complicated involvement in clearance 
of pulmonary edema fluid (38). We have previously shown that 
inhibition of p55 signaling was able to prevent caspase-8 activa-
tion within epithelial cells and thus allow maintenance of barrier 
function and alveolar fluid clearance (18). Inhibition of TNF 
may also aid fluid clearance by reduction of downstream CXCL1 
expression (seen in the current study), the human homolog of 
which (CXCL8) depresses fluid transport (39). However, TNF 
has also been shown in opposition to this, to promote clearance 
of water from the lung via direct activation of epithelial sodium 
channels (40), prevention of which could be highly damaging. We 
did not evaluate alveolar fluid clearance in this study, but there 
was no clear evidence that our treatment regime had adverse 
effects on physiological parameters, possibly because the fluid 
clearance promoting activity of TNF seemingly occurs mainly 
through a receptor-independent pathway (41). Within our acute 
experiments, the earliest detectable consequence of p55 inhibi-
tion occurred around 120 min after acid injury, at which point 
elastance started to diverge from dummy dAb-treated animals. 
Future study of such early time points may therefore yield impor-
tant information regarding the links between TNF, leukocytes, 
and physiological injury.
In the current study, we chose to use a prophylactic strategy 
of dosing animals before induction of injury to identify the true 
potential of p55 inhibition using the dAb. Once their lungs are 
significantly injured by acid to the level comparable to clinical 
ARDS, mice do not tolerate anesthesia and intra-airway drug 
delivery (either intratracheal or intranasal) very well. For this 
reason, it was not possible to give repeated dosings of antibody, 
which may have enhanced or prolonged the protective effects 
observed. The domain antibody used within this study has been 
formulated specifically for airway administration and has a very 
short half-life in the circulation, so unfortunately systemic dosing 
to explore later consequences was also not possible here. Future 
work may include testing of a recently characterized p55-targeting 
dAb (DMS5540, GSK), which has been modified to provide an 
extended circulating half-life (42), although it remains unclear 
whether this would be able to penetrate into the alveolar space 
(or indeed whether this would be necessary). While it could be 
argued that prophylactic dosing in preclinical models of disease 
may not represent the most clinically relevant scenario, it is 
perhaps not so unreasonable in the case of ARDS. Recent studies 
report that up to 75% of patients suffering from ARDS acquired 
or developed it after entering hospital or during their ICU stay 
(43, 44). Identification of treatments that work safely when deliv-
ered prophylactically to “at risk” patients, or very early during 
the onset of disease, may therefore be a useful strategy to prevent 
progression to ARDS, although the same interventions should 
not be expected to be therapeutically efficacious in patients with 
established disease.
In conclusion, our data show clearly that targeting of the p55 
TNFR with use of an intrapulmonary domain antibody attenu-
ates many physiological indications of acid aspiration-induced 
lung injury, including respiratory mechanics, blood gases, and 
markers of edema/permeability. These data show the persistent 
importance of p55 TNF signaling in both the very acute and later 
phases of lung injury, and thus strongly support a role for p55 
inhibition in patients with or at risk of lung injury, an approach 
that is currently being developed clinically. Although in the 
current study the beneficial effects were mainly lost after 24 h of 
injury, the protection up to this point was achieved with just a 
single intranasal dosing. Subsequent experiments will be neces-
sary to determine the potential for modified dosing regimes to 
prolong the attenuation in injury observed.
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